Citigroup
PROF

Citigroup’s Profound Medical PROF Stock Holding History

Citigroup’s Portfolio PROF Stock Details PROF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1
Closed -$8 – 6298
2025
Q4 		$8 Buy
+1
New +$6 ﹤0.01% 5828

Other funds holding PROF

Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
TIM
Timelo Investment Management Aurora, Ontario, Canada $127M AUM 23.73% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
GA
Gagnon Advisors New York $136M AUM 21.55% 1-Year Est. Return
LBA
Letko, Brosseau & Associates Montreal, Quebec, Canada $6.2B AUM 38.92% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
ZCP
Z3 Capital Partners Richmond, Virginia $395M AUM
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

Citigroup's PROF Position: Q1 2026 in Review

Citigroup sold out of Profound Medical (PROF) in Q1 2026, closing a stake of 1 share — an estimated $8 sold.

Citigroup first reported a position in PROF in Q4 2025 and held it in 1 quarter. The position peaked at $8 in Q4 2025. 57 funds tracked by Wall St. Rank hold PROF as of Q1 2026.

  • Citigroup reported no remaining Profound Medical position as of Q1 2026 after selling out during the quarter.
  • Citigroup sold 1 Profound Medical share in Q1 2026, an estimated $8.
  • Citigroup first reported a position in Profound Medical in Q4 2025 and held it in 1 quarter.
  • Citigroup's Profound Medical position peaked at $8 in Q4 2025.
  • 57 funds tracked by Wall St. Rank held Profound Medical as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.